However, d120 seroconversion improved across all patient cohorts [oncologic malignancies under PD-L1 inhibitor therapies (81% to 100%), myeloid neoplasms (82% to 97%), lymphoid neoplasms (48% to 66%)]. Here, CD274 is linked to lymphoid neoplasm.